NCT07586215

HER2-PET: Predicting T-DXd Efficacy and HER2 Heterogeneity

RecruitingOBSERVATIONAL

Trial Details

Start: 2024-11-11Est. Completion: 2026-11-11

Enrollment target: 100 participants

Locations

Fudan Cancer Hospital, Shanghai, China

Contact

Juan Jin Attending physicianmedjinjuan@126.com 15996290233

Other microbiome trials you might be interested in

Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low TrialPhase 3Recruiting

Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage IIIA Breast Cancer AJCC v8Anatomic Stage IIIC Breast Cancer AJCC v8Estrogen Receptor-Positive Breast CarcinomaHER2-Negative Breast Carcinoma

This phase III trial compares standard of care hormone therapy plus ribociclib to chemotherapy followed by hormone thera…

Jonesboro, United StatesEst. completion Jul 31, 2029

View Trial →

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast CancerPhase 1Recruiting

Metastatic Breast Cancer

Apply or Learn More on ClinicalTrials.gov

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.